Here are the Form 4 insider transactions from InMed Pharmaceuticals Inc. (INM) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow INM and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full INM filings page.
InMed Pharmaceuticals Inc. (INM) reported that private investment funds managed by ADAR1 Capital Management, LLC purchased 4 common shares at $1.32 per share on October 23, 2026. The reported post-transaction position was 956,584 shares. The funds hold the securities directly; ADAR1, a ten-percent owner, and Daniel Schneeberger, a ten-percent owner and the LLC’s sole manager, may be deemed indirect beneficial owners. No Rule 10b5-1 plan is reported for the purchase.
InMed Pharmaceuticals Inc. (INM) reports that private investment funds managed by ADAR1 Capital Management, LLC purchased 1,086 common shares on October 19, 2026, and 1 common share on October 16, 2026, each at $1.32 per share. The shares may be deemed indirectly beneficially owned by ADAR1 and Daniel Schneeberger, ADAR1’s sole manager. No Rule 10b5-1 plan is reported.
InMed Pharmaceuticals Inc. (INM) reports that private investment funds managed by ADAR1 Capital Management, LLC purchased 564 shares at $1.3300 on October 13, 2026; 8,021 at $1.3300 on October 14, 2026; and 984 at a $1.3219 weighted average on October 15, 2026. The October 15 purchases ranged from $1.3200 to $1.3300, inclusive. The funds’ shares may be deemed indirectly beneficially owned by ADAR1 Capital Management and Daniel Schneeberger, its sole manager; both are listed as ten-percent owners and disclaim beneficial ownership except to the extent of any pecuniary interest. No Rule 10b5-1 plan is reported.
InMed Pharmaceuticals Inc. (INM) reports that private investment funds managed by ADAR1 Capital Management, LLC purchased 10,903 common shares across October 6–8, 2026. The funds purchased 5,601 shares at a weighted average price of $1.3277 on October 6, 3,046 shares at $1.3300 on October 7, and 2,256 shares at a weighted average price of $1.3283 on October 8. No Rule 10b5-1 plan is reported.
The shares are owned directly by the funds and may be deemed indirectly beneficially owned by ADAR1 Capital Management, LLC and Daniel Schneeberger, its sole manager; both are identified as ten percent owners. Each reporting person disclaims beneficial ownership except to the extent of any pecuniary interest.
InMed Pharmaceuticals Inc. (INM) reported that private investment funds managed by ADAR1 Capital Management, LLC purchased 42,920 common shares in three transactions. The funds purchased 16,431 shares at a weighted-average price of $1.3298 per share on October 1, 2026; 8,307 shares at $1.3300 on October 2, 2026; and 18,182 shares at $1.3300 on October 5, 2026. The October 1 purchases ranged from $1.3200 to $1.3300 per share. ADAR1 Capital Management, LLC and Daniel Schneeberger, its sole manager, are identified as 10% owners, and the shares may be deemed indirectly beneficially owned by them. No Rule 10b5-1 plan is reported.
InMed Pharmaceuticals Inc. (INM) reported that private investment funds managed by ADAR1 Capital Management, LLC, a ten percent owner, made open-market purchases of a total of 91,101 common shares on September 14–16, 2026, at weighted average prices around $1.29 per share.
The shares are held by ADAR1-managed funds and may be deemed indirectly beneficially owned by ADAR1 Capital Management, LLC and Daniel Schneeberger, who each disclaim beneficial ownership except to the extent of any pecuniary interest. No Rule 10b5-1 trading plan is reported.
Private investment funds managed by ADAR1 Capital Management, LLC, a ten percent owner of InMed Pharmaceuticals, purchased 1,000 Common Shares on July 15, 2026 at $1.555 per share, increasing their indirect holdings to 801,000 shares. ADAR1 and Daniel Schneeberger may be deemed indirect owners but each disclaims beneficial ownership except for any pecuniary interest. The transaction was not marked as pursuant to a Rule 10b5-1 trading plan.
Vivo Opportunity–affiliated entities reported open-market purchases totaling 20,546 Common Shares of InMed Pharmaceuticals Inc. at $1.55 per share on July 14–16, 2026. The trades, made through Vivo Opportunity Fund Holdings, L.P. and Vivo Opportunity Cayman Fund, L.P., brought their holdings to 743,057 and 75,019 shares, respectively. Vivo Opportunity, LLC and Vivo Opportunity Cayman, LLC, as general partners, disclaim beneficial ownership beyond their pecuniary interests.
InMed Pharmaceuticals Inc. reported that investment entities affiliated with Vivo Opportunity made a series of open-market purchases of its Common Shares. Over June 30 to July 2, 2026, Vivo Opportunity Cayman Fund, L.P. and Vivo Opportunity Fund Holdings, L.P. together bought 6,551 shares at weighted average prices around $1.54–$1.55 per share in multiple transactions within stated price ranges. Following these purchases, Cayman Fund indirectly held 73,135 shares and Fund Holdings indirectly held 724,395 shares, with general partners Vivo Opportunity, LLC and Vivo Opportunity Cayman, LLC disclaiming beneficial ownership except for their pecuniary interest.
InMed Pharmaceuticals Inc. reported significant insider buying by entities associated with Vivo Opportunity. Over multiple open-market purchases from May 20 to June 8, 2026, Vivo Opportunity Fund Holdings, L.P. and Vivo Opportunity Cayman Fund, L.P. acquired a combined 249,227 common shares at prices generally between $1.42 and $1.75 per share. The funds’ general partners, Vivo Opportunity, LLC and Vivo Opportunity Cayman, LLC, are listed as reporting persons but each disclaims beneficial ownership beyond its pecuniary interest.
Private investment funds managed by ADAR1 Capital Management, LLC bought 468,551 InMed Pharmaceuticals common shares in open-market transactions on May 19, 2026. Individual trades included 200,000 shares at $1.4990, 200,000 shares at $1.5604, and 68,551 shares at $1.5998, all reported as indirect ownership. Footnotes state the securities are owned directly by ADAR1-managed funds and may be deemed indirectly beneficially owned by ADAR1 and Daniel Schneeberger, who each disclaim beneficial ownership beyond their pecuniary interest.
InMed Pharmaceuticals Inc. reported that one of its directors had an employee stock option position expire involving 14 derivative securities on December 15, 2025. These employee stock options related to 14 common shares and carried a U.S. dollar exercise price of $1,397.97, converted from a Canadian dollar exercise price of C$1,925.00 at an exchange rate of C$1.3770 = US$1.00. After this transaction, the director beneficially owned 961 derivative securities with direct ownership.
InMed Pharmaceuticals Inc. reported an insider derivatives transaction involving its President & CEO and Director, Eric A. Adams, dated 12/15/2025. The filing shows an employee stock option labeled "Employee Stock Option (Expiration)" tied to 250 derivative securities related to the company's common shares.
The option carried a U.S. dollar exercise price of $1,397.97 per the form, calculated from a Canadian dollar exercise price of C$1,925.00 using an exchange rate of C$1.3770 = $US1.00. Following this reported transaction, Adams directly beneficially owns 14,050 derivative securities.
InMed Pharmaceuticals Inc.'s Chief Operating Officer, as a single reporting person, filed a Form 4 detailing an insider derivatives transaction with the company.
On 12/15/2025, an employee stock option labeled as an expiration and linked to 60 common shares was reported, with a US$1,397.97 exercise price, converted from a C$1,925.00 exercise price using an exchange rate of C$1.3770 = $US1.00. After this transaction, 7,445 derivative securities were reported as beneficially owned on a direct basis.
InMed Pharmaceuticals Inc. reported an insider transaction by officer Eric C. Hsu, who serves as Sr. VP, Pre-Clinical Res/Dev, involving employee stock options dated 12/15/2025.
The filing shows an employee stock option labeled as an expiration covering 70 common shares, with an exercise price of $1,397.97, converted from a Canadian dollar exercise price of C$1,925.00 using an exchange rate of C$1.3770 = $US1.00. The option had an exercisable date of 12/16/2020 and an expiration date of 12/15/2025. Following this transaction, Hsu beneficially owned 5,280 derivative securities, held directly.